Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  Mylan NV    MYL   NL0011031208

MYLAN NV (MYL)
My previous session
Most popular
  Report  
 SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
11/07/2018 11/08/2018 11/09/2018 11/12/2018 11/13/2018 Date
36.55(c) 37.15(c) 36.95(c) 35.94(c) 35.76(c) Last
8 031 613 5 604 924 4 300 437 4 262 866 4 186 000 Volume
+0.33% +1.64% -0.54% -2.73% -0.50% Change
More quotes
Financials (USD)
Sales 2018 11 471 M
EBIT 2018 3 391 M
Net income 2018 453 M
Debt 2018 12 360 M
Yield 2018 -
Sales 2019 11 987 M
EBIT 2019 3 667 M
Net income 2019 1 237 M
Debt 2019 10 656 M
Yield 2019 -
P/E ratio 2018 17,15
P/E ratio 2019 13,81
EV / Sales2018 2,68x
EV / Sales2019 2,43x
Capitalization 18 439 M
More Financials
Company
Mylan NV is a pharmaceutical healthcare company.The firm engages in the development, license, manufacture, market and distribution of generic, branded generic and specialty pharmaceutical products.It operates through the following geographical segments: North America, Europe, Rest of World, and... 
Sector
Pharmaceuticals
Calendar
02/27Earnings Release
More about the company
Surperformance© ratings of Mylan NV
Trading Rating : Investor Rating :
More Ratings
Latest news on MYLAN NV
11:51aPfizer loses blockbuster drug patent fight in UK Supreme Court
RE
11/13MYLAN : Sc 13g/a
PU
11/09MYLAN : Theravance Biopharma and Mylan Receive FDA Approval for YUPELRI™ (..
PU
11/08Stada, Angelini among final bidders for $1 billion Bristol-Myers' UPSA unit -..
RE
11/06MYLAN : 10-q
PU
11/06Drugmaker Mylan's profit beats; puts no timeline on strategic options
RE
11/05MYLAN : Q3 2018 Non-GAAP Reconciliations
PU
11/05MYLAN : Reports Third Quarter 2018 Results and Reaffirms 2018 Guidance
PR
11/02AbbVie sees hit to Humira sales from European competition
RE
11/02AbbVie sees hit to Humira sales from European competition
RE
More news
Sector news : Pharmaceuticals - NEC
12:50pCANOPY GROWTH : Canadian marijuana firm Canopy Growth posts bigger quarterly net..
RE
11:51aPfizer loses blockbuster drug patent fight in UK Supreme Court
RE
09:39aSouth Korea regulator says Samsung BioLogics intentionally breached accountin..
RE
08:48aBAYER : Weedkiller Lawsuits Mount At Bayer
DJ
08:15aSHIRE : Rule 2.9 Announcement
DJ
More sector news : Pharmaceuticals - NEC
Latest Tweets
11/13$MYL New Form SC 13G/A for Mylan NV From our Stock News Alerts App 
11/13Mylan, Theravance win FDA approval for COPD drug: Theravance Biopharma and My.. 
11/12Former #MNWild winger Mark Parrish set to join NHL Network as studio analyst ..
1
11/12Mylan and Theravance’s COPD treatment gets FDA approval  
11/12Mylan stock price target raised to $48 from $47 at Leerink #news 
More tweets
Qtime:175
News from SeekingAlpha
06:35aPfizer loses Lyrica patent fight 
06:24aDropbox Is A Buy - Cramer's Lightning Round (11/13/18) 
11/13ADAMIS : Here We Go Again! 
11/13THERAVANCE : Why Yupelri Can Become A Blockbuster 
11/13Express Scripts launches new formulary aimed at reducing drug costs 
Chart MYLAN NV
Duration : Period :
Mylan NV Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends MYLAN NV
Short TermMid-TermLong Term
TrendsBullishNeutralBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 17
Average target price 44,6 $
Spread / Average Target 25%
EPS Revisions
Managers
NameTitle
Heather M. Bresch Chief Executive Officer & Executive Director
Rajiv Malik President & Executive Director
Robert J. Coury Executive Chairman
Haribabu Bodepudi Chief Operating Officer
Kenneth Scott Parks Chief Financial Officer
Sector and Competitors
1st jan.Capitalization (M$)
MYLAN NV-15.06%18 439
--.--%0
--.--%0